The study revealed that PD-L1+CD20+ % and PD-1+CD20+ % were significantly increased in patients with advanced disease stages (Figure 3), assuming that these cells might act as indicators of DLBCL progression. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.